Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia [1]

Journal of Clinical Psychiatry

Volumn 63, Issue 9, 2002, Pages 838-

  Anghelescu, Ion ^a   Klawe, Christoph ^a   Dahmen, Norbert ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DOXEPIN; MIRTAZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGRANULOCYTOSIS; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; SLEEP DISORDER; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036737044     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0914a     Document Type: Letter

References (5)

1. Albertini RS, Penders TM. Agranulocytosis associated with tricyclics. J Clin Psychiatry 1978;39:483-485
2. Hartmann PM. Mirtazapine: a newer antidepressant. Am Fam Physician 1999;59:159-161
3. Draper BM, Manoharan A. Neutropenia with cross-intolerance between two tricyclic antidepressant agents. Med J Aust 1987; 146:452-453
4. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-59S
5. Souid AK. Congenital cyclic neutropenia. Clin Pediatr 1995;34: 151-155